Geoff McDonough compensation by year
Generation Bio Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $605,863 | $630,097 | $655,301 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $1,216,875 | $396,984 | $0 |
| Option awards | $1,810,800 | $904,896 | $790,358 |
| Non-equity incentive | $333,224 | $381,209 | $360,416 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $2,077 | $2,199 |
| Total | $3,966,762 | $2,315,263 | $1,808,274 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Generation Bio Co. DEF 14A filed April 23, 2025, accession 0001558370-25-005263, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Generation Bio Co. filed document, accession 0001558370-25-005263. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 47,459 | $50,307 | — |
| Option | 15,687 | — | $30.25 |
| Option | 117,185 | — | $6.49 |
| Option | 94,921 | — | $4.71 |
| Option | 120,234 | — | $1.39 |
| Option | 506,250 | — | $1.86 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Generation Bio Co.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
25 Form 4 lines since the FY2024 proxy (filed April 23, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-09 | U | — | 22,646 | — | 0 |
| 2026-02-09 | U | — | 27,500 | — | 0 |
| 2026-02-09 | Disposition to the issuer derivative | — | 19,903 | — | 0 |
| 2026-02-09 | Disposition to the issuer derivative | — | 25,099 | — | 0 |
| 2026-02-09 | Disposition to the issuer derivative | — | 37,499 | — | 0 |
| 2026-02-09 | Disposition to the issuer derivative | — | 50,624 | — | 0 |
| 2026-02-09 | Disposition to the issuer derivative | — | 90,168 | — | 0 |
| 2026-02-09 | U | — | 138,492 | — | 0 |
The 8 most recent of 25 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Generation Bio discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $656,352 | $12,577 | $0 | $1,029,923 |
| Change in control and involuntary termination | $984,528 | $50,307 | $0 | $1,576,325 |
Per the Potential Payments Upon Termination or Change in Control table in Generation Bio Co.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
Generation Bio’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Geoff McDonough · this page | President and Chief Executive Officer | $1,808,274 |
| Matthew Stanton | Chief Scientific Officer | $993,038 |
| Antionette Paone | Chief Operating Officer | $931,962 |
| Phillip Samayoa | Chief Strategy Officer | $931,763 |
| Matthew Norkunas | Chief Financial Officer | $914,246 |
Board service
Generation Bio board · FY2024How this board is paid
Company policy: Generation Bio pays directors a $40,000 cash retainer. As stated in Generation Bio's FY2024 proxy.
The full Generation Bio compensation record
free company briefThis page is one person within Generation Bio's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Generation Bio proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Generation Bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.